The purpose of the study is to research the standard and individualized treatment model for relapse and refractory lymphatic system malignant tumors.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
50
Unnamed facility
Beijing, Beijing Municipality, China
RECRUITINGoverall response rate
Time frame: 2 years after treatment
complete response
Time frame: 2 years after treatment
progression-free survival
Time frame: 2 years after treatment
overall survival
Time frame: 2 years after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.